RU2476239C2 - On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях - Google Patents

On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях Download PDF

Info

Publication number
RU2476239C2
RU2476239C2 RU2010145048/15A RU2010145048A RU2476239C2 RU 2476239 C2 RU2476239 C2 RU 2476239C2 RU 2010145048/15 A RU2010145048/15 A RU 2010145048/15A RU 2010145048 A RU2010145048 A RU 2010145048A RU 2476239 C2 RU2476239 C2 RU 2476239C2
Authority
RU
Russia
Prior art keywords
cancer
chemotherapeutic agent
nucleotide analogue
plk
administration
Prior art date
Application number
RU2010145048/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010145048A (ru
Inventor
Антонио ХИМЕНО
Мануэль Медина ИДАЛЬГО
Original Assignee
Де Джонс Хопкинс Юниверсити
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Де Джонс Хопкинс Юниверсити filed Critical Де Джонс Хопкинс Юниверсити
Publication of RU2010145048A publication Critical patent/RU2010145048A/ru
Application granted granted Critical
Publication of RU2476239C2 publication Critical patent/RU2476239C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
    • A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
    • A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
RU2010145048/15A 2008-04-17 2008-04-17 On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях RU2476239C2 (ru)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/005104 WO2009128805A1 (en) 2008-04-17 2008-04-17 On01910. na enhances chemotherapeutic agent activity in drug-resistant tumors

Publications (2)

Publication Number Publication Date
RU2010145048A RU2010145048A (ru) 2012-05-27
RU2476239C2 true RU2476239C2 (ru) 2013-02-27

Family

ID=41199352

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010145048/15A RU2476239C2 (ru) 2008-04-17 2008-04-17 On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях

Country Status (10)

Country Link
US (2) US8962614B2 (OSRAM)
EP (1) EP2271339A4 (OSRAM)
JP (1) JP5479453B2 (OSRAM)
KR (1) KR101707669B1 (OSRAM)
CN (1) CN102056607B (OSRAM)
AU (1) AU2008354754B2 (OSRAM)
CA (1) CA2721722C (OSRAM)
NZ (1) NZ588749A (OSRAM)
RU (1) RU2476239C2 (OSRAM)
WO (1) WO2009128805A1 (OSRAM)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2686313C2 (ru) * 2015-02-25 2019-04-25 Байонир Корпорейшн Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102056607B (zh) * 2008-04-17 2014-07-30 约翰·霍普金斯大学 On01910.na促进在抗药性肿瘤中化学治疗剂的活性
ES2864681T3 (es) * 2012-12-07 2021-10-14 Onconova Therapeutics Inc Tratamiento del cáncer hematológico refractario a un agente contra el cáncer
WO2015116696A1 (en) 2014-01-28 2015-08-06 Massachusetts Institute Of Technology Combination therapies and methods of use thereof for treating cancer
HUE052968T2 (hu) 2014-04-30 2021-05-28 Fujifilm Corp Liposzóma kompozíció és annak elõállítási eljárása
CN107922456A (zh) * 2015-08-28 2018-04-17 浙江海正药业股份有限公司 磷酸氟达拉滨的晶型及其制备方法和用途
CN109232403A (zh) * 2017-07-10 2019-01-18 亚宝药业集团股份有限公司 作为蛋白激酶抑制剂的酰胺类前药衍生物
AU2019288048B2 (en) * 2018-06-20 2022-08-11 Fujifilm Corporation Combined medicine comprising gemcitabine-encapsulated liposome composition and immune checkpoint blockade
PL4048284T4 (pl) * 2019-10-21 2025-11-03 Acura Nanomedicine Corporation Metoda leczenia nowotworów
US20230263783A1 (en) 2022-02-18 2023-08-24 Massachusetts Institute Of Technology Cancer treatment by combined inhibition of polo-like kinase and microtubule polymerization

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194711C2 (ru) * 1997-01-24 2002-12-20 Норск Хюдро Аса Производные гемцитабина
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US20070203210A1 (en) * 2006-02-27 2007-08-30 John Frederick Boylan Thiazolyl-benzimidazoles

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006006948A2 (en) 2002-11-14 2006-01-19 Dharmacon, Inc. METHODS AND COMPOSITIONS FOR SELECTING siRNA OF IMPROVED FUNCTIONALITY
US20050043233A1 (en) * 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
US20070197538A1 (en) 2004-10-07 2007-08-23 Mark Nesbit Anti-vascular and anti-proliferation methods, therapies, and combinations employing specific tyrosine kinase inhibitors
CA2593523C (en) * 2005-01-05 2014-04-08 Temple University - Of The Commonwealth System Of Higher Education Treatment of drug-resistant proliferative disorders
JP5278968B2 (ja) * 2006-08-30 2013-09-04 テンプル・ユニバーシティ−オブ・ザ・コモンウェルス・システム・オブ・ハイアー・エデュケイション 骨髄異形性症候群及び急性骨髄性白血病の治療のための組成物及び方法
EP2073803B1 (en) * 2006-10-12 2018-09-19 Astex Therapeutics Limited Pharmaceutical combinations
US20080279874A1 (en) * 2007-05-07 2008-11-13 Wyeth Compositions and methods for modulation of plk1 kinase activity
CN102056607B (zh) * 2008-04-17 2014-07-30 约翰·霍普金斯大学 On01910.na促进在抗药性肿瘤中化学治疗剂的活性

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2194711C2 (ru) * 1997-01-24 2002-12-20 Норск Хюдро Аса Производные гемцитабина
US7037906B1 (en) * 2000-12-22 2006-05-02 Oxigene, Inc. Methods for modulating tumor growth and metastasis
US20060128777A1 (en) * 2004-11-05 2006-06-15 Bendall Heather H Cancer treatments
US20070203210A1 (en) * 2006-02-27 2007-08-30 John Frederick Boylan Thiazolyl-benzimidazoles

Non-Patent Citations (8)

* Cited by examiner, † Cited by third party
Title
GUAN R. et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53 - defective, oncogenic transformed cells and inhibits tumor growth in animals Cancer Res. 2005 Apr 1;65(7):2698-704. [онлайн] [найдено 2012.02.15] *
GUAN R. et al. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53 - defective, oncogenic transformed cells and inhibits tumor growth in animals Cancer Res. 2005 Apr 1;65(7):2698-704. [онлайн] [найдено 2012.02.15] (Найдено из базы данных PubMed PMID:). *
GUMIREDDY К. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plkl, is a potent anticancer agent. Cancer Cell. 2005 Mar; 7 (3):275-86. Реферат [онлайн] [найдено 2012.02.15]. Найдено из базы данных PubMedPMID: 15766665. *
GUMIREDDY К. et al. ON01910, a non-ATP-competitive small molecule inhibitor of Plkl, is a potent anticancer agent. Cancer Cell. 2005 Mar; 7 (3):275-86. Реферат [онлайн] [найдено 2012.02.15]. Найдено из базы данных PubMedPMID: 15766665. МИХАЙЛОВ И.Б. Настольная книга врача по клинической фармакологии. - СПб.: Фолиант, 2001, с.615-630, раздел «цитарабин». ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ. - М.: РЛС, 2001, с.209, статья «гемцитабин», с.841, статья «тегафур», с.945, статья «флуороурацил». *
LANSING TJ. Et al. In vitro biological activity of a novel small-molecule inhibitor of polo-like kinase 1. Mol Cancer Ther. 2007 Feb; 6(2):450-9 [онлайн] [найдено 2012.02.15] (Найдено из базы данных PubMed PMID: 17267659). *
МИХАЙЛОВ И.Б. Настольная книга врача по клинической фармакологии. - СПб.: Фолиант, 2001, с.615-630, раздел «цитарабин». *
ПЕРЕВОДЧИКОВА Н.И. Гемцитабин (Гемзар) и его место в современной противоопухолевой химиотерапии ND 07 №09-00292. - Русский медицинский журнал, 2007, т.15, №25 [онлайн] [найдено 2012.02.15] (Найдено из базы данных YNDEX). *
ЭНЦИКЛОПЕДИЯ ЛЕКАРСТВ. - М.: РЛС, 2001, с.209, статья «гемцитабин», с.841, статья «тегафур», с.945, статья «флуороурацил». *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2686313C2 (ru) * 2015-02-25 2019-04-25 Байонир Корпорейшн Фармацевтическая композиция для лечения рака, содержащая микроРНК в качестве активного ингредиента
US10351849B2 (en) 2015-02-25 2019-07-16 Bioneer Corporation Pharmaceutical composition for treating cancer comprising microrna as active ingredient
US10612026B2 (en) 2015-02-25 2020-04-07 Bioneer Corporation Pharmaceutical composition for treating cancer comprising microrna as active ingredient

Also Published As

Publication number Publication date
US20110201675A1 (en) 2011-08-18
CA2721722C (en) 2015-12-08
CN102056607A (zh) 2011-05-11
AU2008354754A1 (en) 2009-10-22
JP5479453B2 (ja) 2014-04-23
KR101707669B1 (ko) 2017-02-16
US20150209381A1 (en) 2015-07-30
US8962614B2 (en) 2015-02-24
CN102056607B (zh) 2014-07-30
KR20100137570A (ko) 2010-12-30
EP2271339A4 (en) 2011-09-28
CA2721722A1 (en) 2009-10-22
NZ588749A (en) 2012-06-29
JP2011518153A (ja) 2011-06-23
WO2009128805A1 (en) 2009-10-22
EP2271339A1 (en) 2011-01-12
US9545418B2 (en) 2017-01-17
RU2010145048A (ru) 2012-05-27
AU2008354754B2 (en) 2014-09-11

Similar Documents

Publication Publication Date Title
RU2476239C2 (ru) On01910.na, усиливающий активность химиотерапевтического агента в резистентных к лекарственным средствам опухолях
US20240390401A1 (en) Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
EP2786754B1 (en) Combination therapy with a mitotic inhibitor
CN108136207A (zh) 用于治疗癌症的联合疗法
JP5377968B2 (ja) 癌治療のために単独で用いるまたは化学療法薬と併用するヒストンデアセチラーゼ（ｈｄａｃ）阻害剤
KR20140079831A (ko) 췌장암 및／또는 담도암 치료약
WO2010086964A1 (ja) がん治療のための併用療法
US20200297743A1 (en) Combination of bcl-2/bcl-xl inhibitors and chemotherapeutic agent and use thereof
US11890292B2 (en) Compositions, methods, systems and/or kits for preventing and/or treating neoplasms
TWI827310B (zh) 異硫氰酸酯結構修飾化合物於預防或治療肝臟疾病之用途
US12319915B2 (en) Cytotoxic fluoropyrimidine polymers and methods of use thereof
JP2024518509A (ja) Ｐａｒｐ阻害剤抵抗性癌治療剤
US10434086B2 (en) Combination therapies with curaxins
TW202317128A (zh) 治療化療相關的胃腸道副作用的化合物和方法
CN116889566A (zh) 安吖啶在治疗β-catenin突变型肝癌中的应用
JP2004514683A (ja) レバミゾール及び５−フルオロウラシルの同時投与法
HK1202419B (en) Combination therapy with a mitotic inhibitor
HK1138797A (zh) 肝癌治疗剂

Legal Events

Date Code Title Description
MM4A The patent is invalid due to non-payment of fees

Effective date: 20180418